Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)

Condition:   Anemia Interventions:   Drug: Vadadustat;   Drug: Darbepoetin alfa Sponsors:   Akebia Therapeutics;   Otsuka Pharmaceutical Development& Commercialization, Inc. (OPDC) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials